Design Therapeutics Inc Market Cap ($430.65 Million)
Market Cap & Net Worth: Design Therapeutics Inc (DSGN)
Design Therapeutics Inc market cap. Design Therapeutics Inc (NASDAQ:DSGN) has a market capitalization of $430.65 Million ($430.65 Million) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12659 globally and #3162 in its home market, demonstrating a 1.81% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Design Therapeutics Inc's stock price $10.68 by its total outstanding shares 56963757 (56.96 Million). Also see DSGN operating cash flow for how efficiently the company converts equity into cash flow.
Design Therapeutics Inc Market Cap History (2021–2026)
Design Therapeutics Inc market cap history from 2021 to 2026. Data shows change from $1.22 Billion to $608.37 Million (-21.52% CAGR). Check current stock price of Design Therapeutics Inc for real-time trading data and today's change.
Index Memberships
Design Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.02% | #346 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #1262 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.02% | #192 of 263 |
Weight: Design Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Design Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Design Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Design Therapeutics Inc net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of DSGN by Market Capitalization
Companies near Design Therapeutics Inc in the global market cap rankings as of November 1, 2026. Also see DSGN total asset value for a full breakdown of the balance sheet.
Key companies related to Design Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Design Therapeutics Inc (2021–2026)
Market capitalization of Design Therapeutics Inc from 2021 to today. Between 2021 and today, Design Therapeutics Inc's market cap moved from $1.22 Billion to $ 608.37 Million, with a yearly change of -21.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $608.37 Million | +13.86% |
| 2025 | $534.32 Million | +52.03% |
| 2024 | $351.47 Million | +132.83% |
| 2023 | $150.95 Million | -74.17% |
| 2022 | $584.45 Million | -52.08% |
| 2021 | $1.22 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Design Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $430.65 Million USD |
| MoneyControl | $430.65 Million USD |
| MarketWatch | $430.65 Million USD |
| marketcap.company | $430.65 Million USD |
| Reuters | $430.65 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Design Therapeutics Inc
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potenti… Read more